|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Intra-Cellular Therapies, Inc.
| | | Phone: | (646) 440-9333 | Fax: | (646) 440-9334 | Year Established: | 2002 | Ticker: | ITCI | Exchange: | NASDAQ | Main Contact: | Allen A. Fienberg, Ph.D., Founder & VP, Business Development | | Other Contacts: | Andrew Satlin M.D., Executive VP & CMO Lawrence P. Wennogle, Ph.D., VP, Drug Discovery Lawrence J. Hineline, CPA, VP, Finance & CFO Robert E. Davis, PhD, Senior VP & CSO Kimberly E. Vanover, Ph.D., Senior VP, Clinical Development Michael Halstead, JD, Senior VP & General Counsel Sharon Mates, Ph.D., Founder, Chairman & CEO Suresh Durgam M.D, Senior VP, Late Stage Clinical Development Mark Neumann, Executive VP & CCO
| | Company Description | Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. | |
|
|
|
|
|